Development of new ionic gelation strategy: Towards the preparation of new monodisperse and stable hyaluronic acid/β-cyclodextrin-grafted chitosan nanoparticles as drug delivery carriers for doxorubicin

Abstract

In the present study, β-cyclodextrin-grafted chitosan nanoparticles (β-CD-g-CS NPs) were prepared using a new ionic gelation strategy involving a synergistic effect of NaCl (150 mmol/L), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, 10 mmol/L), and water bath sonication. This new strategy afforded smaller and more monodisperse β-CD-g-CS NPs vs. the classical ionic gelation method. New HA/β-CD-g-CS NPs were also prepared using the above-mentioned strategy by adding hyaluronic acid (HA) to the β-CD-g-CS copolymer at different weight ratios until the ZP values conversion. The best result was obtained with the weight ratio of w(HA):w(β-CD-g-CS) = 2:1 and furnished new spherical and smooth HA/β-CD-g-CS NPs. Furthermore, the stability of β-CD-g-CS NPs and HA/β-CD-g-CS NPs at 4°C in physiological medium (pH 7.4) was compared for 3 weeks period and showed that HA/β-CD-g-CS NPs were more stable all maintaining their monodispersity and high negative ZP values compared to β-CD-g-CS NPs. Finally, preliminary study of HA/β-CD-g-CS NPs as carrier for the controlled release of the anticancer drug doxorubicin was investigated. These new HA/β-CD-g-CS NPs can potentially be used as drug delivery and targeting systems for cancer treatment.

Keywords

β-cyclodextrin-grafted chitosan / hyaluronic acid / ionic gelation / drug delivery / physicochemical parameters control

References

[1] Dey A, Koli U, Dandekar P, . Investigating behaviour of polymers in nanoparticles of chitosan oligosaccharides coated with hyaluronic acid. Polymer, 2016, 93: 44–52

[2] Al-Qadi S, Grenha A, Remuñán-López C. Chitosan and its derivatives as nanocarriers for siRNA delivery. Journal of Drug Delivery Science and Technology, 2012, 22(1): 29–42

[3] Al-Qadi S, Alatorre-Meda M, Zaghloul E M, . Chitosan–hyaluronic acid nanoparticles for gene silencing: The role of hyaluronic acid on the nanoparticles’ formation and activity. Colloids and Surfaces B: Biointerfaces, 2013, 103: 615–623

[4] Amidi M, Mastrobattista E, Jiskoot W, . Chitosan-based delivery systems for protein therapeutics and antigens. Advanced Drug Delivery Reviews, 2010, 62(1): 59–82

[5] Szejtli J. Introduction and general overview of cyclodextrin chemistry. Chemical Reviews, 1998, 98(5): 1743–1754

[6] Duchêne D, Bochot A. Thirty years with cyclodextrins. International Journal of Pharmaceutics, 2016, 514(1): 58–72

[7] Otero-Espinar F J, Torres-Labandeira J J, Alvarez-Lorenzo J C, . Cyclodextrins in drug delivery systems. Journal of Drug Delivery Science and Technology, 2010, 20(4): 289–301

[8] Zhang J, Ma P X. Cyclodextrin-based supramolecular systems for drug delivery: recent progress and future perspective. Advanced Drug Delivery Reviews, 2013, 65(9): 1215–1233

[9] Prabaharan M, Mano J F. Chitosan derivatives bearing cyclodextrin cavities as novel adsorbent matrices. Carbohydrate Polymers, 2006, 63(2): 153–166

[10] Zhang X G, Wu Z M, Gao X J, . Chitosan bearing pendant cyclodextrin as a carrier for controlled protein release. Carbohydrate Polymers, 2009, 77(2): 394–401

[11] Lu L, Shao X, Jiao Y, . Synthesis of chitosan-graft-β-cyclodextrin for improving the loading and release of doxorubicin in the nanoparticles. Journal of Applied Polymer Science, 2014, 131(21): 41034

[12] Yuan Z, Ye Y, Gao F, . Chitosan-graft-β-cyclodextrin nanoparticles as a carrier for controlled drug release. International Journal of Pharmaceutics, 2013, 446(1–2): 191–198

[13] Zhang H, Oh M, Allen C, . Monodisperse chitosan nanoparticles for mucosal drug delivery. Biomacromolecules, 2004, 5(6): 2461–2468

[14] Fan W, Yan W, Xu Z, . Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. Colloids and Surfaces B: Biointerfaces, 2012, 90: 21–27

[15] Nasti A, Zaki N M, de Leonardis P, . Chitosan/TPP and chitosan/TPP-hyaluronic acid nanoparticles: systematic optimisation of the preparative process and preliminary biological evaluation. Pharmaceutical Research, 2009, 26(8): 1918–1930

[16] Jonassen H, Kjoniksen A L, Hiorth M. Effects of ionic strength on the size and compactness of chitosan nanoparticles. Colloid & Polymer Science, 2012, 290(10): 919–929

[17] Sawtarie N, Cai Y, Lapitsky Y. Preparation of chitosan/tripolyphosphate nanoparticles with highly tunable size and low polydispersity. Colloids and Surfaces B: Biointerfaces, 2017, 157: 110–117

[18] Gokce Y, Cengiz B, Yildiz N, . Ultrasonication of chitosan nanoparticle suspension: influence on particle size. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2014, 462: 75–81

[19] Kedjarune-Leggat U, Supaprutsakul C, Chotigeat W. Ultrasound treatment increases transfection efficiency of low molecular weight chitosan in fibroblasts but not in KB cells. PLoS One, 2014, 9(3): e92076

[20] So M H, Ho C M, Chen R, . Hydrothermal synthesis of platinum-group-metal nanoparticles by using HEPES as a reductant and stabilizer. Chemistry – An Asian Journal, 2010, 5(6): 1322–1331

[21] Stern R, Kogan G, Jedrzejas M J, . The many ways to cleave hyaluronan. Biotechnology Advances, 2007, 25(6): 537–557

[22] Sivadas N, O’Rourke D, Tobin A, . A comparative study of a range of polymeric microspheres as potential carriers for the inhalation of proteins. International Journal of Pharmaceutics, 2008, 358(1–2): 159–167

[23] Kalam M A. Development of chitosan nanoparticles coated with hyaluronic acid for topical ocular delivery of dexamethasone. International Journal of Biological Macromolecules, 2016, 89: 127–136

[24] Li L, Qian Y, Jiang C, . The use of hyaluronan to regulate protein adsorption and cell infiltration in nanofibrous scaffolds. Biomaterials, 2012, 33(12): 3428–3445

[25] Lokeshwar V B, Mirza S, Jordan A. Targeting hyaluronic acid family for cancer chemoprevention and therapy. Advances in Cancer Research, 2014, 123: 35–65

[26] Mok H, Park J W, Park T G. Antisense oligodeoxynucleotide-conjugated hyaluronic acid/protamine nanocomplexes for intracellular gene inhibition. Bioconjugate Chemistry, 2007, 18(5): 1483–1489

[27] Melton L D, Slessor K N. Synthesis of monosubstituted cyclohexaamyloses. Carbohydrate Research, 1971, 18(1): 29–37

[28] Gonil P, Sajomsang W, Ruktanonchai U R, . Novel quaternized chitosan containing β-cyclodextrin moiety: Synthesis, characterization and antimicrobial activity. Carbohydrate Polymers, 2011, 83(2): 905–913

[29] Kievit F M, Wang F Y, Fang C, . Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. Journal of Controlled Release, 2011, 152(1): 76–83

[30] Ji J, Hao S, Liu W, . Preparation, characterization of hydrophilic and hydrophobic drug in combine loaded chitosan/cyclodextrin nanoparticles and in vitro release study. Colloids and Surfaces B: Biointerfaces, 2011, 83(1): 103–107

[31] Yuan Z, Ye Y, Gao F, . Chitosan-graft-β-cyclodextrin nanoparticles as a carrier for controlled drug release. International Journal of Pharmaceutics, 2013, 446(1–2): 191–198

[32] Prabaharan M, Gong S. Novel thiolated carboxymethyl chitosan-g-β-cyclodextrin as mucoadhesive hydrophobic drug delivery carriers. Carbohydrate Polymers, 2008, 73(1): 117–125

[33] Ito T, Iida-Tanaka N, Niidome T, . Hyaluronic acid and its derivative as a multi-functional gene expression enhancer: protection from non-specific interactions, adhesion to targeted cells, and transcriptional activation. Journal of Controlled Release, 2006, 112(3): 382–388

[34] Deng X, Cao M, Zhang J, . Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials, 2014, 35(14): 4333–4344

[35] Singh R, Lillard J W Jr. Nanoparticle-based targeted drug delivery. Experimental and Molecular Pathology, 2009, 86(3): 215–223

RIGHTS & PERMISSIONS

Higher Education Press and Springer-Verlag GmbH Germany, part of Springer Nature